Digestive tract pathology

Summary

The group has a wide range of interests, including various gastrointestinal system diseases (gastrointestinal bleeding, inflammatory bowel diseases and diverticular disease) and focusses on colorectal cancer.
Its extensive experience in clinical trials and surgical studies is complemented with collaborations with basic research groups, creating valuable knowledge in the field, in order to optimise both chemotherapy treatments and surgical protocols in patients with rectal cancer.

550 Publications

Strategic lines

Selected Publications

Serra Aracil,X;Pericay,C;Badia Closa,J;Golda,T;Biondo,S;Hernández,P;Tarragona,E et al, Short-term outcomes of chemoradiotherapy and local excision vs total mesorectal excision in T2-T3ab,N0,M0 rectal cancer. A multicentre randomised, controlled, phase III trial (the TAUTEM study)., Ann. Oncol., 2023;34(1):78-90, doi:10.1016/j.annonc.2022.09.160
Fundora,Y;Hessheimer,AJ;Del Prete,L;Maroni,L;Lanari,J;Barrios,O;Clarysse,M et al, Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis, J. Hepatol., 2023;78(4):794-804, doi:10.1016/j.jhep.2023.01.007
Correa Bonito,A;Cerdán Santacruz,C;Di Martino,M;Blanco Terés,L;Gancedo Quintana,Á; Martín Pérez,E;Biondo,S et al, Treatment for acute uncomplicated diverticulitis without antibiotherapy: systematic review and meta-analysis of randomized clinical trials., Int. J. Surg., 2023;109(5):1412-1419, doi:10.1097/JS9.0000000000000307
Chaparro,M;Acosta,D;Rodriguez,C;Mesonero,F;Vicuna,M;Barreiro de Acosta,M;Fernandez Clotet,A et al, Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety, Am. J. Gastroenterol., 2023;118(7):1237-1247, doi:10.14309/ajg.0000000000002145
Serrano,I;Luque,A;Ruiz Cerulla,A;Navas,S;Blom,AM;de Córdoba,SR;Fernández,FJ et al, C4BP(ß-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patients, Pharmacol. Res., 2023;197106948-106948, doi:10.1016/j.phrs.2023.106948

Selected Projects

18ACL129. AN OBSERVATIONAL PROSPECTIVE LONG-TERM EXPOSURE REGISTRY OF ADJULT PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS. ICON Clinical Research UK No2 limited. Budget: 186.800€. 2018- . PI: Guardiola Capón, Jordi.
14ACL125. REGISTRO NO INTERVENCIONISTA DE LARGA DURACIÓN PARA EVALUAR LA SEGURIDAD Y LA EFECTIVIDAD DE HUMIRA® (ADALIMUMAB) EN PACIENTES CON COLITIS ULCEROSA (CU) DE ACTIVIDAD MODERADA A GRAVE (LEGACY). MAPI SAS. Budget: 94.640€. 2014- . PI: Guardiola Capón, Jordi.
18ACL053. ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE. Budget: 76.000€. 2018-2024. PI: Guardiola Capón, Jordi.
19ACL036. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de crohn que respondan al tratamiento de inducción en los estudios M16-006, M15-991 o que hayan completado el estudio M15-989. Abbvie Biotherapeutics Inc. Budget: 40.722€. 2019- . PI: Guardiola Capón, Jordi.
PUB22004. Estudio prospectivo y multicéntrico sobre factores clínico-biológicos predictivos de Diverticulitis CRÓnica de colon (DICRO). Hospital Universitario de Bellvitge. Budget: 19.450€. 2022-2025. PI: Climent Agustín, Marta.